About Blueprint Medicines
Blueprint Medicines is a Healthcare company based in Cambridge (United States) founded in 2008, and was acquired by Sanofi in June 2025. Selective kinase inhibitors are developed for genomically defined cancers. Blueprint Medicines has raised $115 million across 4 funding rounds from investors including Royalty Pharma, Sanofi and TD Securities. The company has 201 employees. Blueprint Medicines has completed 1 acquisition, including Lengo Therapeutics. Its website blueprintmedicines.com draws about 17 thousand monthly visits. Blueprint Medicines offers products and services including Avapritinib, Elenestinib, and BLU-808. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Blueprint Medicines Corporation. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Blueprint Medicines was founded in 2008 and is headquartered in Cambridge, United States. Operations focus on the biotechnology sector, where selective kinase inhibitors are developed for patients with genomically defined cancers. The approach involves analysis of genetic drivers in cancer and other kinase-related diseases, supported by a proprietary library of chemical compounds. Targets that are difficult to drug are addressed through this method.
- Headquarters Cambridge, United States
- Employees 201
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website blueprintmedicines.com
- Social LinkedIn X
- Acquired by Sanofi (Jun 2025)
- Legal Name Blueprint Medicines Corporation
- Annual Revenue$17.31 M (USD)-92as on Dec 31, 2023
- Net Profit-$67.09 M (USD)87as on Dec 31, 2024
- EBITDA$80.32 M (USD)116as on Dec 31, 2024
- Total Equity Funding$115M (USD)
in 4 rounds
- Latest Funding Round$1.25B (USD), Post-IPO
Jun 2022
- InvestorsRoyalty Pharma
& 14 more
- Employee Count201
- Investments & Acquisitions
- Acquired bySanofi
(Jun 2025)
Products & Services of Blueprint Medicines
Blueprint Medicines offers a comprehensive portfolio of products and services, including Avapritinib, Elenestinib, and BLU-808.
Treats systemic mastocytosis and gastrointestinal stromal tumors.
Targets indolent and advanced systemic mastocytosis.
Addresses chronic urticaria and other mast cell diseases.
Funding Insights of Blueprint Medicines
Blueprint Medicines has successfully raised a total of $115M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.25 billion completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $115M
- Total Rounds 4
- Last Round Post-IPO — $1.25B
- First Round $40M
(May 2012)
- Investors Count 14
All 4 funding rounds of Blueprint Medicines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $1.25B | Post-IPO | – | – | |
| Nov 2014 | $50M | Series C | – | Cowen, Perceptive Advisors | – |
| Jan 2014 | $25M | Series B | – | Nextech Invest | |
| May 2012 | $40M | Series A | – | Third Rock Ventures |
15 investors in total: 15 institutional.
Investors in Blueprint Medicines
Blueprint Medicines has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Royalty Pharma, Sanofi and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Provides AI and data analytics consulting services to enhance business strategies. | 2018 | sixthroad.com | Islamabad, Pakistan | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for Blueprint Medicines
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Blueprint Medicines
162 people are tracked at Blueprint Medicines (110 in leadership, 6 in board & advisors, 46 in team); the tracked headcount is 201.
| Name | Role | Group |
|---|---|---|
Rachel Ambroziak | Associate Director, Talent Attraction | Leadership |
Elaine Shelly | Associate Director, Clinical Outsourcing | Leadership |
Betel Girmay | Vice President, Clinical Operations | Leadership |
Christopher Shea | Director, Digital Quality And Computerized Systems Compliance, Qs&c | Leadership |
Kate Haviland | CEO | Leadership |
Percy Carter | Chief Scientific Officer | Leadership |
Debbie Durso-Bumpus | Chief People Officer | Leadership |
Becker Hewes | Chief Medical Officer | Leadership |
Mike Landsittel | CFO | Leadership |
Fouad Namouni | President, Research & Development | Leadership |
Helen Shanahan | Director, Compensation, Mobility And People Analytics | Leadership |
Ilda Bidollari | Senior Medical Director, Drug Safety | Leadership |
Wendy Ankrom | Vice President, Head Of Clinical Pharmacology | Leadership |
Zhaoxia Yang | Director | Leadership |
Andrew Law | Senior Director, Global Business Communications | Leadership |
Casaundra Copeland | Corporate Account Director | Leadership |
Anitha Suram | Director, Clinical Pharmacology | Leadership |
Maria Roche | Vice President Clinical Development | Leadership |
Theresa Moran | Associate Director Clinical Operations | Leadership |
Kristin Britton | Associate Director Market Access Marketing | Leadership |
142 more people are available in the full profile.
Complete people profiles for Blueprint Medicines
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Blueprint Medicines
Blueprint Medicines has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lengo Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Precision medicines for oncology are developed using covalent drug-target technology. | lengotx.com | San Diego, United States | 2020 | Nov 2021 | $250M |
Complete acquisition details for Blueprint Medicines
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Blueprint Medicines
6 dated milestones of Blueprint Medicines across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Blueprint Medicines is founded.
- Funding First funding round of $40.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Lengo Therapeutics.
- Funding Latest funding round, Post-IPO, of $1.2B.
- Exit Acquired by Sanofi.
Competitors of Blueprint Medicines
Blueprint Medicines has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Blueprint Medicines
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Blueprint Medicines
The website of Blueprint Medicines (blueprintmedicines.com) receives about 17.2K visits a month and ranks #1,495,010 among all websites worldwide, #1,965 in Biotechnology and Pharmaceuticals.
- Monthly visits17.2K
▼ 7.9% vs previous month
- Unique visitors7.7K
per month
- Global rank#1,495,010
among all websites
- Category rank#1,965
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.6
- Average visit12 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Blueprint Medicines. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellarity.com | 100% | 5.8K | #2,884,812 | View details | |
| bio-itworld.com | 88% | #1,672,238 | View details | ||
| prothena.com | 88% | 5.6K | #3,145,374 | View details | |
catabasis.com | catabasis.com | 87% | – | ||
| bluebirdbio.com | 87% | 9.1K | #3,210,476 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Blueprint Medicines
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Blueprint Medicines (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Blueprint Medicines
Complete news archive for Blueprint Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blueprint Medicines
Blueprint Medicines was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Blueprint Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Blueprint Medicines is a funded company, having raised a total of $115M across 4 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on May 2012.
Blueprint Medicines has 201 employees.
Annual revenue of Blueprint Medicines is $17.31M as on Dec 31, 2023.
Blueprint Medicines was founded in 2008 and is headquartered in Cambridge, United States. Operations focus on the biotechnology sector, where selective kinase inhibitors are developed for patients with genomically defined cancers. The approach involves analysis of genetic drivers in cancer and other kinase-related diseases, supported by a proprietary library of chemical compounds. Targets that are difficult to drug are addressed through this method.
Blueprint Medicines offers Avapritinib, Elenestinib, and BLU-808.
Blueprint Medicines has made 1 acquisition, including Lengo Therapeutics.
Blueprint Medicines has 15 investors. Key investors include Royalty Pharma, Sanofi, TD Securities, RA Capital, and Perceptive Advisors.
Blueprint Medicines operates through Blueprint Medicines Corporation.
Yes. Blueprint Medicines was acquired by Sanofi in June 2025.